Search Engine: "What We Got Wrong About GLP-1s"

Host: PJ Vogt
Guest: Dr. Rachel Bedard (Internist, Geriatrician, Palliative Care Specialist, Writer)
Airdate: April 10, 2026

Episode Overview

This episode explores what popular culture and the media got wrong about GLP-1 drugs (like Ozempic and Wegovy), looking beyond weight-loss fads and celebrity controversies to their actual, transformative impact on real medical patients—especially vulnerable populations. Host PJ Vogt sits down with Dr. Rachel Bedard to discuss her on-the-ground experience prescribing GLP-1s in homeless and marginalized communities, revealing surprising effects and neglected stories. The conversation also addresses shifting concepts of medicine, the ethics of off-label use, and the ongoing cultural conversation about medicalizing personal dissatisfaction and self-improvement.

Key Discussion Points & Insights

1. The GLP-1 Cultural Explosion—and Media Discourse

• GLP-1s' Sudden Prominence: PJ notes how, from 2022–2023, GLP-1 drugs like Ozempic rapidly became a cultural lightning rod, associated everywhere with rapid weight loss, celebrity use, and moral panic online.

  “Going online felt like walking into a crazy shootout at an old western saloon, except instead of gunslingers, it was all fast draw scolders.” – PJ (02:10)

• Media Fails to Capture Reality: The media conversation was disproportionately focused on cosmetic and body image implications—mostly among affluent, media-connected people—while ignoring the drug’s actual use in treating chronic illnesses.

  “It just highlighted how much cultural discourse about bodies, even illness, medicine … almost never reflects the experience of people who are actually ill.” — Dr. Bedard (19:22)

2. Dr. Rachel Bedard’s Background & Perspective

• Unique Clinical Experience: Dr. Bedard trained as an internist and specialized in geriatrics and palliative care, but spent six years as a physician on Rikers Island, and now works in a homeless clinic embedded in a New York City public hospital.

  • Her patient population is primarily unhoused or precariously housed, with high rates of mental health, addiction and chronic physical illness.
  • She’s navigated both elite media environments (as a NYT writer) and the city’s most marginalized communities.

• Social Determinants of Health: She emphasizes that illness is inseparable from social context for any patient, but that marginalized patients face uniquely severe barriers to care.

  “The doctor ends up … negotiating with the world on behalf of my patients to get them things I think they need.” — Dr. Bedard (13:57)
  “Health is socially determined to a large degree.” (14:09)

3. GLP-1s: Medical Mechanisms and Real Impact

A. How GLP-1 Drugs Work (26:23–33:04)

• Mechanisms:

  • Slow gastric emptying: Stomach stays full longer => more satiety, less hunger.
  • Hormonal modulation: Increases insulin release in response to high glucose; helps control blood sugar (esp. for diabetics).
  • Effects on the brain: Works on reward circuits, possibly reducing addictive behaviors.

• Observed Outcomes: Substantial weight loss (10–15% of body weight in a year), improved diabetes control, reduced cardiovascular events, improved pain and inflammation, possible beneficial spillovers to addiction and mental health.

  “These drugs, by the end of 2023, we knew that they had an all-cause mortality benefit. That’s unbelievable as an outcome.” — Dr. Bedard (17:54)

B. Unexpected Benefits and Research

• Beyond Weight Loss:
  • Possible cancer prevention (esp. for obesity-linked cancers like breast/colon).
  • Experimental trials in Alzheimer’s, Parkinson’s, and broader anti-inflammatory action.
  • Improvements in arthritis and heart failure noted anecdotally and in early studies.

  “There are a million things that are like question marky things that look good.” (33:13)

• Addiction Modulation: GLP-1s’ action on brain reward systems is leading to research on treating alcohol and even behavioral addictions.

C. Risks and Side Effects

• Common Side Effects: Nausea, vomiting, constipation—major reasons people stop the drugs.
• Possible Psychiatric Effects: Some evidence and concern about depression or increased suicidality, but large studies have not confirmed serious risks.

  “There are certainly … 5 to 10% of people who don’t tolerate them because the side effects are too much.” (38:26)

• Long-term Unknowns: Not enough decades-long trial data yet; rare cancers are a concern in certain at-risk individuals.

4. GLP-1s in Vulnerable Patient Populations (36:07–40:30)

• Access Via Safety Net: Due to New York City’s strong Medicaid and hospital pharmacy systems, many of Dr. Bedard’s homeless and low-income patients gained early and reliable access to these drugs, unlike patients elsewhere.

• Clinical Revolution:

  • Diabetic patients experience major improvements across many health measures.
  • “For people for whom it works, it works better than any other single intervention I’ve ever given someone other than curative ones.” (39:48)
  • Medically, it’s “an extraordinary thing to be able to offer them” — improving pain, depression, blood pressure, cholesterol, overall wellbeing.

  “Most of my patients are on eight to ten medicines a day. And for them to be able to take one shot a week … lose weight, improve their diabetes, high blood pressure, high cholesterol … that’s an extraordinary thing.” (39:13)

• contrast with Elite Narrative: The media focused on cosmetic use and body image, missing these life-changing effects in chronic, underserved patients.

5. Why Did GLP-1s Finally Become Affordable? (40:30)

• Supply & Demand: Unexpectedly, public demand and shortages caused compounding pharmacies to produce generic or compounded versions, pushing monthly prices from $1,200 to as low as $150.
• For once, the healthcare market “kind of, sort of worked.”

6. Off-Label Use, Ethics, and Culture (44:02–50:20)

• Off-Label Support: Dr. Bedard is generally supportive of off-label GLP-1 use in cases like postpartum weight gain, or carefully monitored for people wanting to reduce drinking—but caveats apply for patients with histories of eating disorders or those at risk for rare side effects.

• Notable Moment:

  “I know one guy who was taking it so that he would post on Twitter less.” (45:17)

• Emerging ‘Lifestyle Medicine’: There’s a cultural shift—especially among the affluent—toward viewing drugs as tools for self-optimization, not just treatment of disease.

  “Peptides, GLP-1s, the cosmetic procedure stuff—it’s like all part of a thing of, like: I don’t feel the way I want to feel in my body, I don’t look the way that I want to look … I’m going to seek medical intervention to help me become the thing that I want to become.” — Dr. Bedard (48:32)

• Host’s Summation:

  • Cosmetic and Medical Blurring: Are we just more comfortable with cosmetic procedures, or are we “medicalizing” normal life and aging?

  “I think that we have, in a weird way, medicalized a lot of the experience of being … in the human life cycle.” — Dr. Bedard (49:25)

  • Dr. Bedard expresses unease but also intellectual honesty about not having fully resolved views on this new paradigm.

Most Memorable Quotes

• “There are very few things in medicine where you can show that it prevents people from dying over a very short period of time of taking the drug. And this did that.” – Dr. Bedard (17:54)
• “For people for whom it works … it works better than any other single intervention I’ve ever given someone, other than curative ones.” – Dr. Bedard (39:48)
• “My patients … their experience of the weather is really different than my experience of the weather, because they are exposed to the elements in ways I am not … That’s a really different way to be in a body in the same spaces that I’m in my body in.” – Dr. Bedard (08:08)
• “I haven’t weighed this much since 1996 and I died.” — Patient of Dr. Bedard, via Dr. Bedard (38:10)
• “I think we have in a weird way medicalized a lot of the experience of being … in the human life cycle.” – Dr. Bedard (49:25)

Timestamps for Major Segments

• GLP-1 Cultural Panic & Personal Discomfort – 02:00–04:30
• Dr. Bedard’s Clinical Background & Social Context – 04:38–13:04
• GLP-1 Medical Mechanisms & Benefits – 26:23–33:13
• Real-World Effects on Marginalized Patients – 36:07–40:30
• The New Cultural Paradigm: Drugs for "Feeling Better" – 44:02–50:20
• The Blurring of Cosmetic & Medical, and Dr. Bedard’s Uncertainty – 47:01–50:23

Conclusion

This episode of Search Engine reveals how the media’s portrayal of GLP-1s missed the true revolutionary impact the drugs have had in the lives of medically vulnerable patients, focusing instead on body image and celebrity discourse. Dr. Bedard’s firsthand accounts offer a corrective, showing that GLP-1s are far more than cosmetic agents—they are transformative medicines that improve, and at times save, lives. The episode also raises crucial questions about the evolving meaning of medicine in a culture where treatment and self-improvement are becoming ever more entangled.

Further listening: PJ notes that a related, extra conversation—about “cause medicine” and the ongoing expansion of cosmetic/medical interventions—can be found as a bonus for subscribers.